Weight Loss Medications Overview for 2026
Photo by Tima Miroshnichenko on Pexels
Obesity is recognized as a chronic disease by the American Medical Association, the Obesity Medicine Association, and the World Health Organization. For adults who meet specific clinical criteria, FDA-approved anti-obesity medications can be an evidence-based component of care, used alongside nutrition, movement, sleep, and behavioral support. They are not lifestyle products, they are not appropriate for everyone, and they should always be prescribed and monitored by a licensed clinician.
This 2026 educational overview describes the major FDA-approved weight-loss medications neutrally — what they are, how they work, who they are typically indicated for, common side effects, and approximate costs. It is not medical advice, and nothing here should be used to self-diagnose or self-prescribe.
Important: Weight-loss medications are prescription drugs with potential side effects. They are FDA-approved for specific indications and BMI thresholds. This article describes them neutrally for educational purposes. Always consult a licensed physician — never obtain GLP-1 or other weight-loss medications outside a regulated prescribing relationship.
How This Guide Works
We pulled FDA labeling, NIH summaries, and published trial data to describe each medication. Costs reflect typical 2026 US cash pricing and are subject to change. Insurance coverage and manufacturer savings programs significantly affect what patients actually pay. We do not rank “best” medications because prescribing decisions are individual.
Medication Snapshot
| Drug | Class | FDA Indication (US) | Route | Cash Price (2026) |
|---|---|---|---|---|
| Wegovy (semaglutide) | GLP-1 | Chronic weight management, BMI ≥30 or ≥27 + comorbidity | Weekly injection | ~$1,350/mo |
| Zepbound (tirzepatide) | GIP/GLP-1 | Chronic weight management, same BMI thresholds | Weekly injection | ~$1,060/mo |
| Ozempic (semaglutide) | GLP-1 | Type 2 diabetes (weight loss is off-label) | Weekly injection | ~$970/mo |
| Mounjaro (tirzepatide) | GIP/GLP-1 | Type 2 diabetes | Weekly injection | ~$1,070/mo |
| Saxenda (liraglutide) | GLP-1 | Chronic weight management, same BMI thresholds | Daily injection | ~$1,350/mo |
| Contrave | Naltrexone-bupropion | Chronic weight management, same BMI thresholds | Oral, twice daily | ~$100–$700/mo with savings |
| Qsymia | Phentermine-topiramate | Chronic weight management, same BMI thresholds | Oral, daily | ~$200/mo with savings |
| Phentermine | Sympathomimetic | Short-term (weeks) weight management | Oral, daily | Generic, low cost |
| Orlistat (Xenical/Alli) | Lipase inhibitor | Chronic weight management | Oral, with meals | $30–$80/mo |
The FDA’s BMI thresholds for chronic weight-management medications are generally BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. These are guideline thresholds, not personal targets.
GLP-1 and GIP/GLP-1 Medications
Wegovy (semaglutide 2.4 mg)
Wegovy was FDA-approved in 2021 for chronic weight management. In the STEP 1 trial, participants taking semaglutide 2.4 mg with lifestyle support lost an average of approximately 15% of body weight at 68 weeks. Common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — particularly during dose titration.
Zepbound (tirzepatide)
Zepbound was FDA-approved in late 2023. SURMOUNT-1 reported an average of approximately 20% weight loss at 72 weeks on the 15 mg dose. Its mechanism activates both GIP and GLP-1 receptors.
Ozempic and Mounjaro
Both are FDA-approved for type 2 diabetes, not weight loss. They have driven significant public interest because of secondary weight reductions, but prescribing them for weight loss in patients without diabetes is off-label and depends on clinician judgment, insurance, and access.
Saxenda (liraglutide)
Saxenda is a daily GLP-1 injection FDA-approved for chronic weight management. Trial data shows average loss around 5–8% with lifestyle support — less than the weekly options but a longer track record.
Non-GLP-1 Medications
Contrave (naltrexone-bupropion)
Contrave combines low-dose naltrexone (an opioid antagonist) with bupropion (an antidepressant). It is thought to affect reward and appetite pathways. Common side effects include nausea, headache, constipation, insomnia, and blood pressure changes. It is contraindicated in seizure disorders, uncontrolled hypertension, and several other situations.
Qsymia (phentermine-topiramate)
Qsymia combines phentermine (a stimulant appetite suppressant) with topiramate (an antiseizure medication). Trial data shows average weight loss of approximately 8–10% with lifestyle support. Contraindications include pregnancy, glaucoma, hyperthyroidism, and recent MAOI use.
Phentermine
Phentermine alone is approved for short-term (typically up to 12 weeks) appetite suppression. It is a sympathomimetic with potential effects on blood pressure and heart rate. Long-term outcomes are limited and prescribing is regulated.
Orlistat (Xenical/Alli)
Orlistat blocks pancreatic lipase, reducing dietary fat absorption. It is the only FDA-approved weight-loss medication available without a prescription in the US (Alli, lower dose). GI side effects — oily stools, urgency, flatulence — are common, especially with higher-fat meals. Modest weight-loss effect (about 3–5% average).
Side Effect and Contraindication Matrix
| Drug | Common Side Effects | Notable Contraindications |
|---|---|---|
| Wegovy / Saxenda | Nausea, vomiting, diarrhea | Personal/family history of medullary thyroid cancer, MEN 2, pregnancy |
| Zepbound | Nausea, GI symptoms | Same as above |
| Ozempic / Mounjaro | Nausea, GI symptoms | Same; off-label for weight loss alone |
| Contrave | Nausea, headache, insomnia | Seizure disorder, uncontrolled hypertension, MAOI use |
| Qsymia | Dry mouth, cognitive effects, tingling | Pregnancy, glaucoma, hyperthyroidism |
| Phentermine | Increased HR/BP, insomnia | Cardiovascular disease, hyperthyroidism, MAOI use |
| Orlistat | GI symptoms with high-fat meals | Chronic malabsorption, cholestasis |
This is a non-exhaustive summary; your prescriber will review your full history.
Insurance, Cost, and Access in 2026
Coverage for anti-obesity medication varies widely:
- Many commercial plans cover Wegovy and Zepbound with prior authorization for adults meeting BMI thresholds.
- Medicare historically excluded coverage for weight-loss indications, though policy changes are ongoing.
- Manufacturer savings cards can substantially lower out-of-pocket costs for eligible insured patients.
- Cash prices remain high; compounded versions sold outside regulated pharmacies have been the subject of FDA safety warnings.
How to Talk to Your Doctor
- List current medications and supplements, including OTC products.
- Share personal and family history of thyroid cancer, pancreatitis, gallbladder disease, kidney disease, and disordered eating.
- Ask which medication, if any, matches your situation.
- Discuss what success looks like for you — energy, labs, function — not just a number on the scale.
- Confirm side-effect monitoring, lab follow-up, and what to do if you experience severe symptoms.
Recommended Offers
💡 Editor’s pick — Telehealth obesity medicine: Form Health connects you with board-certified obesity-medicine clinicians for an individualized assessment.
💡 Editor’s pick — Combined behavior + medical: Sequence by Weight Watchers pairs clinician oversight with the WW behavior program for eligible adults.
💡 Editor’s pick — Foundations first: Found’s Foundations program focuses on nutrition and behavior change, with medication available only if and when a clinician deems it appropriate.
FAQ — Weight Loss Medications
Q: Are weight-loss medications safe? A: They are FDA-approved for specific indications with reviewed safety data. All have side effects and contraindications. Always use under clinician supervision.
Q: How long are they meant to be used? A: Chronic-weight-management medications are intended for long-term use in eligible patients. Stopping often leads to weight regain without ongoing lifestyle support.
Q: Can I take them just to “lose 15 pounds”? A: They are not approved for cosmetic use. Eligibility is based on BMI and health criteria.
Q: Do I need to follow a diet while on them? A: Yes. Trial protocols always included structured lifestyle support; outcomes are best when medication is paired with nutrition and movement.
Q: What about compounded GLP-1s? A: They are not FDA-approved drugs. The FDA has issued warnings about safety and dosing errors.
Q: Are over-the-counter “fat burners” effective? A: Most have weak or no evidence and can carry safety risks. Talk to your physician or pharmacist.
Related Reading on Righte Hub
- Ozempic vs Wegovy vs Mounjaro: 2026 Comparison
- Best Medical Weight Loss Programs 2026
- Best Weight Loss Programs of 2026
- Sustainable Weight Loss: Evidence-Based 2026 Guide
- Weight Loss After 40: Realistic Guide for 2026
Final Verdict
Anti-obesity medications are a significant 2026 option for adults who meet clinical criteria and who are working within a relationship with a prescribing clinician. They are most effective when combined with nutrition, movement, sleep, and behavioral support. They are not appropriate for cosmetic use, and they should never be obtained outside a regulated prescribing relationship.
This article is for informational and educational purposes only and is not medical, dietary, or weight-loss advice. Talk to a licensed healthcare professional or registered dietitian before starting any weight-management program, especially if you have any medical conditions or take prescription medications. Righte Hub may receive compensation for some placements; rankings are independent.
By Righte Hub Editorial · Updated May 9, 2026
- weight loss
- weight loss medications
- 2026
- wellness